SecBot SecBot
424B5 ·Filed Nov 20, 2026

CTSO

Cytosorbents Corp
BEARISH
Impact 6/10
Horizonimmediate Processed1d 22h ago SEC0001104659-26-130444
Notable filing: 424B5
Actionable Insight ▼ Bearish

The offering provides near-term liquidity to address the company's negative working capital position ($15.4M current assets vs $28.0M current liabilities) and reduces debt by $5.25M, but at the cost of significant dilution (~35% increase in share count). Monitor the company's cash burn rate and progress toward the planned DrugSorb-ATR De Novo submission in early 2027, as the FDA denial in April 2025 remains a key overhang. The insider participation (96,527 shares at $5.18) provides some alignment but does not offset the dilutive impact.

DirectionBearish
Confidencehigh
Horizonimmediate

CytoSorb

▼ Bearish Named in this 424B5
Impact
Phase
Approved / Commercialized
Time to market
Already on the market (CE-marked in Europe, FDA-cleared in US)
Next catalyst
None dated

What to watchWatch the September 28, 2026 Nasdaq compliance deadline, if CTSO cannot sustain $1.00 for 10 consecutive trading days before then, delisting risk becomes acute. The DrugSorb-ATR FDA De Novo submission (submitted Q1 2026) is a potential positive catalyst but has no announced decision date. The stock is a high-risk micro-cap with limited cash runway and stagnant revenue.

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

CytoSorbents is conducting a registered direct offering of 653,208 shares of common stock (including 96,527 shares to directors and officers at $5.18/share) and pre-funded warrants for 151,822 shares at $4.939/warrant, with gross proceeds of approximately $4.0 million. Concurrently, the company is issuing 202,429 registered shares to Avenue Venture Opportunities Fund to satisfy $1.0 million of debt, part of a broader $5.25 million debt restructuring under the Avenue Amendment. Net cash proceeds of ~$3.5 million will be used to repay $3.0 million of Avenue principal plus fees, with the remainder for working capital. The offering follows Q3 2026 earnings reported 8 days prior, which showed +3% YoY revenue growth and improved net loss, and represents a dilutive capital raise at a $14M market cap.

Key Financial Metrics

Offering Size
$4.0M
Dilution
35.2%
Underwriters
H.C. Wainwright & Co., LLC

Key Facts

  • Registered direct offering of 556,681 shares at $4.94/share and 96,527 shares to insiders at $5.18/share, plus pre-funded warrants for 151,822 shares at $4.939/warrant
  • Gross proceeds of approximately $4.0 million; net proceeds of ~$3.5 million after fees and expenses
  • Concurrent issuance of 202,429 registered shares to Avenue to satisfy $1.0 million of debt; total $2.25 million debt-for-equity swap under Avenue Amendment
  • Cash repayment of $3.0 million principal plus $322,500 in fees to Avenue; total debt reduction of ~$5.25 million
  • Shares outstanding post-offering: 4,261,562 (excluding pre-funded warrant exercise), up from 3,152,889 as of September 30, 2026
  • Dilution of $4.92 per share for new investors at $4.94 offering price; as adjusted net tangible book value of $0.02/share
  • H.C. Wainwright & Co. acting as placement agent with 6.0% cash fee and warrants for 18,078 shares at $6.175/share
  • Company had $5.7 million cash on hand as of September 30, 2026, with current liabilities of $28.0 million exceeding current assets of $15.4 million
  • Q3 2026 revenue of $9.7M (+3% YoY) and net loss of $1.8M, improving from $3.2M loss in Q3 2025
  • Market cap of $14M; offering represents ~29% of pre-offering market cap in gross proceeds

Financial Impact

Gross proceeds of $4.0 million from equity offering; $2.25 million of debt converted to equity; net cash proceeds of ~$3.5 million after fees; total debt reduction of ~$5.25 million

dilutiondebtcashshare count

Risk Factors

  • Immediate and substantial dilution of ~$4.92 per share for new investors; share count increases by ~35% from 3.15M to 4.26M
  • Company had negative working capital of $12.6M as of September 30, 2026, and requires additional financing to fund operations
  • FDA denied DrugSorb-ATR De Novo application in April 2025; resubmission planned for early 2027 with uncertain outcome
  • Up to $19.4M available under ATM facility could lead to further dilution
  • Low market cap ($14M) and high volatility (11.3% normal daily move) amplify price sensitivity to this dilutive event

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001104659-26-130444
Document: 0001104659-26-130444-index-headers.html0001104659-26-130444
Document: 0001104659-26-130444-index.html0001104659-26-130444
Document: 0001104659-26-130444.txt0001104659-26-130444

Track record

12 reports on CTSO

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +36.94% at T+60 after the Aug 6, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 20, 20261d ago 424B5 Bearish 6/10 Viewing Entry $5.39 Now $4.16 +22.82% settles Feb 19
  2. Nov 20, 20261d ago 8-K Bearish 6/10 Entry $5.39 Now $4.16 +22.82% settles Feb 19
  3. Nov 19, 20262d ago 8-K/A Neutral 4/10 Entry $5.13 Now $4.16 −18.91% settles Feb 18
  4. Nov 17, 20265d ago NT 10-Q Neutral 4/10 Entry $4.52 Now $4.16 −7.96% settles Feb 16
  5. Nov 12, 20269d ago Press Release Neutral 4/10 Entry $4.87 Now $4.16 −14.58% settles Feb 11
  6. Nov 12, 20269d ago 8-K Neutral 5/10 No price data
  7. Sep 23, 20268w ago 8-K Mixed 5/10 Entry $4.91 Now $4.16 −15.27% settles Dec 17
  8. Aug 6, 202615w ago Press Release Bearish 6/10 Entry $0.3600 to $0.2270 Now $4.16 −1055.56% ▲ +36.94% +34.68% vs SPY
  9. Jun 25, 202621w ago DEFA14A Neutral 3/10 Entry $0.3620 to $0.2660 Now $4.16 +1049.17% ▼ −26.52% −32.61% vs SPY
  10. Jun 16, 202622w ago Insider Cluster Bullish 6/10 Entry $0.5189 to $0.3205 Now $4.16 +701.70% ▼ −38.23% −40.10% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens Mon (26h 28m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 20, 2026